Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · IEX Real-Time Price · USD
4.710
+0.090 (1.95%)
At close: Apr 18, 2024, 4:00 PM
4.800
+0.090 (1.91%)
After-hours: Apr 18, 2024, 5:19 PM EDT

Orchestra BioMed Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020
Revenue
2.763.53-0.785.7
Revenue Growth (YoY)
-21.88%---
Cost of Revenue
0.190.210.20.15
Gross Profit
2.573.32-0.985.56
Selling, General & Admin
20.2614.037.9310.83
Research & Development
33.8221.9512.8913.48
Operating Expenses
54.0835.9820.8224.31
Operating Income
-51.51-32.66-21.8-18.75
Interest Expense / Income
000.93-0.33
Other Expense / Income
-2.390.950.292.93
Pretax Income
-49.12-33.61-23.01-21.36
Net Income
-49.12-33.61-23.01-21.36
Shares Outstanding (Basic)
331592
Shares Outstanding (Diluted)
331592
Shares Change
121.67%69.97%337.98%-
EPS (Basic)
-1.48-2.24-2.61-10.61
EPS (Diluted)
-1.48-2.24-2.61-10.61
Free Cash Flow
-46.21-29.88-19.7-26.72
Free Cash Flow Per Share
-1.39-1.99-2.23-13.27
Gross Margin
93.26%94.03%-97.46%
Operating Margin
-1866.16%-924.34%--328.81%
Profit Margin
-1779.71%-951.26%--374.45%
Free Cash Flow Margin
-1674.09%-845.74%--468.56%
EBITDA
-48.2-32.82-21.91-21.55
EBITDA Margin
-1746.41%-928.81%--377.85%
Depreciation & Amortization
0.920.790.180.14
EBIT
-49.12-33.61-22.09-21.69
EBIT Margin
-1779.71%-951.26%--380.26%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).